Lilly's Trulicity Shows Unique Cardiovascular Outcomes Benefit, Albeit A Modest One

Eli Lilly & Co. reported the first detailed results from a cardiovascular outcomes trial for the GLP-1 receptor agonist Trulicity (dulaglutide) at the American Diabetes Association's annual meeting on 9 June in San Francisco, showing treatment with Trulicity resulted in a significant 12% reduction in major cardiovascular events in a uniquely broad patient population. But the results were more modest than some investors had expected.

Trulicity competes in a crowded class, so it's unclear if the data will give Trulicity a substantial commercial boost as...